Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
PatSnap Eureka Desktop
NEWAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Law Firms
Life Sciences
High-Tech
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report How does Ac-225 PSMA alpha therapy compare to approved Lu-177 PSMA-617 in mCRPC? PSA50 rates, dosimetry, supply chain, and the emerging pipeline explained.
Article | Report Explore the 2026 natural polymer rheology modifier landscape: key biopolymer types, application domains, leading innovators, and IP trends for formulators and R&D leads.
Article | Report How AI is transforming the way engineering teams identify technology gaps between current capabilities and future product performance requirements. Explore methods and tools.
Article | Report Plastic waste gasification is reshaping circular economy strategy. Explore the 2026 technology landscape: key clusters, hydrogen pathways, refinery integration, and emerging IP signals.
Article | Report How engineers design system-level EMC for mixed HV/LV electronics in EVs — covering shielding, grounding, filtering, and CISPR 25 compliance strategies.
Article | Report GSBR-1290 by Structure Therapeutics is an oral non-peptide GLP-1 receptor agonist advancing to Phase III for obesity. Explore the clinical and IP landscape.
Article | Report Explore the 2026 microplastic-free personal care materials landscape: regulatory drivers, bio-based alternatives, and IP strategy for R&D and formulation teams.
Article | Report VK2735 enters Phase 3 VENTURE with 14.7% weight loss at 13 weeks. How does Viking Therapeutics' dual GIP/GLP-1 agonist compare to tirzepatide — and why is it a top M&A target?
Article | Report How AI transforms the way engineers discover and evaluate biological mechanisms for mechanical engineering problems — from NLP-driven biomimicry search to generative cross-domain design.
Article | Report Explore the edible biopolymer film materials landscape for 2026: polysaccharide, protein, lipid and composite systems across food packaging, pharma, and agri sectors.
Article | Report MicroRNA therapeutics map 2026: clinical translation barriers, delivery platforms, oncology dominance, and emerging antimicrobial & immunotherapy applications.
Article | Report How does cipaglucosidase alfa/miglustat compare to avalglucosidase alfa in Pompe disease? Explore the IP, clinical trial data, and competitive dynamics shaping the next-generation ERT race.
Article | Report How engineers validate long-term corrosion resistance of titanium dental implant surfaces using electrochemical and simulated physiological test methods.
Article | Report The anti-counterfeiting materials landscape in 2026: key technology approaches, innovation trends, and how to navigate patent intelligence in brand protection.
Article | Report How lixisenatide-class GLP-1 receptor agonists protect the brain: ELAD MS trial design, LixiPark Phase II data, and the patent landscape driving neurodegeneration R&D.